The development of bone disease in multiple myeloma: Lessons from the 5TMM murine models of myeloma
Els De Leenheer , M Lawson , Pi Croucher , D Heath
Cancer Treatment Reviews 32 22
2006
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo
Xu , Karin , Isabelle , Camp
中国药理学报：英文版 ( 5) 699 -709
60
2013
Bisphosphonates in the treatment of myeloma bone disease
P. Croucher
European Journal of Haematology 70 ( 4) 271 -272
2003
Regulation of neural crest cell fate by the retinoic acid and Pparg signalling pathways
N. Li , R. N. Kelsh , P. Croucher , H. H. Roehl
Development 137 ( 3) 389 -394
36
2010
Structural mechanisms of trabecular bone loss in man.
J.E. Compston , R.W.E. Mellish , P. Croucher , R. Newcombe
Bone and Mineral 6 ( 3) 339 -350
115
1989
Genetic models of bone disease using ENU mutagenesis
S.D.M. Brown , C.T. Esapa , I. Barbaric , T. Hough
Bone 44 S19
2009
Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma.
A. Chantry , L. Coulton , O. Gallagher , H. Evans
Bone 44 ( 2009)
2009
Deregulation of the bone marrow stromal compartment occurs early in multiple myeloma and precedes osteolytic bone disease
D. Kassen , N. Rabin , D. Lath , P. Croucher
Bone 48
2011
PL5.1. RANK ligand signaling system in malignancy
P. Croucher
Cancer Treatment Reviews 34 45
2008
Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts
J. H. D. Bassett , A. Boyde , P. G. T. Howell , R. H. Bassett
Proceedings of the National Academy of Sciences of the United States of America 107 ( 16) 7604 -7609
104
2010
The anti-tumor potential of zoledronic acid.
R. Coleman , P. Croucher , S. Jagdev
The Breast 12
36
2003
Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
P I Croucher , C M Shipman
Blood 100
2002
Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma
A Hijzen , J Lippitt , B Van Camp , P I Croucher
Blood 98
6
2001
Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro
A J Roelofs , P I Croucher , P A Hulley , C M Shipman
Journal of Bone and Mineral Research 20 ( 7) 1295 -1295
2005
Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
R M Locklin , P I Croucher , C M Shipman , Russell Rgg.
Journal of Bone and Mineral Research 20
2005
Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
M H Helfrich , S H Ralston , R L Soutar , M Greaves
British Journal of Haematology 105 70 -70
1999
Differential sensitivity of normal osteoblast-like cells and osteosarcoma cells to TRAIL and an agonist antibody to TRAIL receptor-2
R M Locklin , P I Croucher , C M Shipman , Russell Rgg.
Journal of Bone and Mineral Research 20 1307 -1307
1
2005
Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
P I Croucher , Russell Rgg. , G S Mueller , K Vanderkerken
Journal of Bone and Mineral Research 19 1037 -1037
2004
OPG is a survival factor for breast- and prostate cancer cells in vitro
F C Hamdy , I Holen , J M Lippitt , P I Croucher
Bone 30
1
2002
Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
I Holen , J M Lippitt , P I Croucher , C M Shipman
Journal of Bone and Mineral Research 15 1217 -1217
2
2000